glp-1 clinical trial GLP1 agonists: current and future landscape of trials for patients with metabolic dysfunction Real-World Evidence for GLP-1 Receptor
Description
Orforgliprons oral delivery route and scalable production capacity position it as a frontrunner in democratizing access to incretin-based therapies, particularly for patients who are hesitant or unable to adhere to injectable regimens
( Figure 2 ) for a more detailed figure, refer to reference 18
Hu X, Xu Q, Wan H, Hu Y, Xing S, Yang H, et al
doi: 10.1186/s13098-024-01412-x
On the other hand, FDA-approved medications like Wegovy and Zepbound offer a proven path to weight loss with significantly lower risks
Identifying optimal dosing regimens may help resolve the context-dependent duality of GLP-1RAs in certain malignancies
